Auris Medical Holding Ltd. (EARS): Price and Financial Metrics


Auris Medical Holding Ltd. (EARS): $3.05

-0.05 (-1.61%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add EARS to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

EARS Stock Price Chart Interactive Chart >

Price chart for EARS

EARS Price/Volume Stats

Current price $3.05 52-week high $6.60
Prev. close $3.10 52-week low $0.73
Day low $3.00 Volume 174,000
Day high $3.09 Avg. volume 3,096,183
50-day MA $3.37 Dividend yield N/A
200-day MA $2.86 Market Cap 34.82M

Auris Medical Holding Ltd. (EARS) Company Bio


Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. The company was formerly known as Auris Medical AG and changed its name to Auris Medical Holding AG in April 2014. The company was founded in 1998 and is based in Zug, Switzerland.


EARS Latest News Stream


Event/Time News Detail
Loading, please wait...

EARS Latest Social Stream


Loading social stream, please wait...

View Full EARS Social Stream

Latest EARS News From Around the Web

Below are the latest news stories about Auris Medical Holding Ltd that investors may wish to consider to help them evaluate EARS as an investment opportunity.

Auris Medical launches new corporate website

Auris Medical Holding (EARS) announces the launch of its newly-designed corporate website www.aurismedical.com. "...the new website reflects the company’s recent strategic move into RNA therapeutics, while highlighting the exciting prospects for its traditional businesses," CEO Thomas Meyer said.Shares down nearly 1% premarket.Auris had announced plans of its strategic repositioning, last month....

Seeking Alpha | July 16, 2021

Auris Medical Announces Launch of New Corporate Website

Hamilton, Bermuda, July 15, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced the launch of its newly-designed corporate website www.aurismedical.com. The new website features a streamlined and modern design and also reflects the Company’s recently announced strategic repositioning. “We are proud to present our projects and products a

Yahoo | July 16, 2021

Auris Medical Announces Publication of Data from Preclinical Studies with Bentrio™ Nasal Spray in Prevention and Mitigation of SARS-CoV-2

Bentrio™ formulation well tolerated in vitro on human nasal epitheliumUp to 99% reduction of SARS-CoV-2 viral titer with prophylactic treatment vs. controlsViral titer reduced 12- or 14-fold vs. controls when treatment started 24 or 30 h post infection Hamilton, Bermuda, July 14, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced addit

Yahoo | July 14, 2021

Auris Medical to Develop KRAS-Targeting RNA Treatment for Colorectal Cancer as First Therapeutic Indication for OligoPhore™ Technology

Treatment of KRAS-driven colorectal cancer selected as first therapeutic indication for OligoPhore™ platformCompany to launch development program under project code AM-401 with aim of IND submission in late 2022 Hamilton, Bermuda, July 6, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced the selection of mutant KRAS-driven colorectal

Yahoo | July 6, 2021

Auris Medical to Initiate Market Launch of Bentrio™ Nasal Spray in Germany

Hamilton, Bermuda, June 28, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced that its affiliate Altamira Medica Ltd. will start the market roll-out of Bentrio™, its nasal spray for protection against airborne viruses and allergens, by launching it in Germany. Bentrio™ will shortly become available through selected online pharmacies;

Yahoo | June 28, 2021

Read More 'EARS' Stories Here

EARS Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year -4.69%
3-year -2.24%
5-year -97.62%
YTD N/A
2021 0.00%
2020 61.73%
2019 -82.24%
2018 -92.27%
2017 -44.86%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6492 seconds.